BioCardia's Heart Failure Cell Therapy Shows 100% Survival At Two Years

 

• BioCardia Inc 
  BCDA+4.12%+ Free Alerts
   announced data from its CardiAMP Cell Therapy for Heart Failure pivotal trial.  
• "The two-year outcomes for patients with heart failure receiving the investigational CardiAMP Cell Therapy in the roll-in cohort showed clinical improvement with 100% survival over two years. These outcomes surpassed our expectations in terms of patient benefit across prespecified primary and secondary endpoints," said Peter Altman, BioCardia's President & CEO.
• "While this smaller cohort is not a head-to-head comparison, the current state of the art therapies for these patients which have been successful in slowing disease, are assessed by us to have 79.9% survival after two years."
• Improvement in median functional capacity as measured by a six-minute walk distance was observed by six months (28.5 m), with a six-minute walk distance maintained through 24 months (31.0 m).
• In the study, 70% of patients reported improved or stable quality of life over 24 months.
• At 24 months, 50% of patients were improved by at least one NYHA class (n=4 at class I), 20% had unchanged NYHA class, and 30% deteriorated by one class, from class II to III.

https://www.benzinga.com/general/biotech/22/10/29121551/biocardias-heart-failure-cell-therapy-shows-100-survival-at-two-years